According to the Epoch Times, the University of Queensland's (UQ) BASE Facility will be responsible for these new mRNA injections. "Demand for mRNA continues to surge," the university said, adding that work is already underway at the lab. The facility is Australia's leading provider of mRNA for research and pilot studies.
UQ associate professor Tim Mercer, the director of the BASE Facility, noted that the mRNA made by the lab will be used for the "next generation" of mRNA injections. "Having the ability to produce mRNA for clinical trials allows us to build the next generation of mRNA vaccines and therapies here in Australia," he said. "It is the key step for our pandemic preparedness, and also us capturing the value of the economic growth of the mRNA industry."
"This technology has been key in our battle against [the Wuhan coronavirus] COVID-19, and is showing great promise to combat other infectious diseases such as cancer and autoimmunity," remarked Seth Cheetham, the BASE Facility's deputy director. Researchers are planning to use mRNA made at the BASE Facility in phase one clinical trials come 2024.
Canberra is providing A$4.3 million ($2.8 million) in funding to the BASE Facility, through the Medical Research Future Fund's National Critical Research Infrastructure Scheme. The state government, meanwhile, is providing $250,000 for the facility. UQ and global healthcare company Sanofi are each delivering $1 million.
The Therapeutic Goods Administration, the Australian equivalent of the U.S. Food and Drug Administration, approved the Pfizer and Moderna mRNA COVID-19 injections for use in the Land Down Under during the COVID-19 pandemic. According to Mercer, the mRNA industry was worth $55 billion in 2022 – and could be worth $107 billion by the year 2030.
But Dr. Peter McCullough, a Texas-based cardiologist, begs to differ when it comes to mRNA injections. During an October online symposium sponsored by the World Council for Health (WCH), he warned that the mRNA COVID-19 injections can cause cancer – citing three ways the vaccines do it.
The first way involves the S2 segment of the SARS-CoV-2 spike protein. According to McCullough, this section "is likely to inhibit tumor suppressor systems," leading to the development of cancers.
The second way shows that mRNA vaccines "impair the natural DNA repair mechanisms of the human body." McCullough explained that spontaneous mutations in the human genome are negated with a natural mechanism that prevents cells from becoming cancerous. "In theory, administering repeated doses of mRNA would impair our body's ability to repair that DNA," he continued.
The third way stems from the recent discovery that mRNA COVID-19 injections contain the Simian Virus 40 (SV40) enhancer. A July 2004 study in Clinical Microbiology Reviews stated that SV40 is a "known oncogenic DNA virus which induces primary brain and bone cancers, malignant mesothelioma and lymphomas in laboratory animals."
In December 2022, McCullough warned in a post on his Substack that those injected with the mRNA COVID-19 shots become walking spike protein factories. According to the cardiologist, the vaccinated could "shed" spike protein to individuals who have chosen not to get the injection – causing the same harms that have befallen those injected with the gene therapy. He cited a paper by French pharmacobiologist Dr. Helene Banoun, which warned that spike protein from the vaccinated may spread to unvaccinated individuals via bodily fluids and secretions such as saliva, sweat and semen.
"Now, the public is grappling with the issue of … spike protein shedding as a potential concern among those who have worked so hard to remain healthy and free of COVID-19 vaccination," McCullough wrote. (Related: BIOWEAPONS FACTORIES: New study finds that the fully vaccinated are shedding mRNA and spike proteins onto the unvaccinated.)
Visit Vaccines.news for more stories about mRNA COVID-19 injections.
Watch Australian lawmaker Russell Broadbent explaining the human cost of COVID-19 vaccine injuries below.
This video is from the HALOROCK channel on Brighteon.com.